TrovaGene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop targeted therapies for the treatment of patients with leukemias, lymphomas and solid tumor cancers. Co.'s drug candidate, onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) adenosine triphosphate competitive inhibitor. PLK1 is essential for regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. Co.'s intellectual property and proprietary technology enables it to analyze circulating tumor DNA and clinically actionable markers for predicting response to cancer therapies. The TROV average annual return 10 years is shown above.
The Average Annual Return on the TROV average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TROV average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TROV average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
